stockrow
Friday 6 November 2026
Export DMAC’s income statement to Excel — free account
DiaMedica Therapeutics, Inc.
DMAC Healthcare Biotechnology
- EPS
- −5.56%
- Free cash flow
- −6.75%
- Total debt
- −90.0%
Quarter to June 2026, against a year earlier
9.46
0.42
+4.65%
Follow DMAC
Alert me
DiaMedica Therapeutics, Inc. (DMAC) P/E ratio
DiaMedica Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2018 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CAPR Capricor Therapeutics, Inc. compare | n/m |
| INDP Indaptus Therapeutics, Inc. compare | n/m |
| CBIO Crescent Biopharma, Inc. compare | n/m |
| DMAC DiaMedica Therapeutics, Inc. | n/m |
| OVID Ovid Therapeutics compare | n/m |
| RGNX REGENXBIO Inc. compare | n/m |
| MDXG MiMedx Group, Inc compare | n/m |
| PBYI Puma Biotechnology, Inc. compare | 15.3× |
| SLBT SL SCIENCE HLDG compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)